DRI Healthcare Trust (DHT-UN) Q1 2026 earnings summary

Executive summary

• Achieved record Q1 total income of $50.6 million, up 15% year-over-year, with 18% royalty income growth and strong operational momentum.

• Adjusted EBITDA reached $52.8 million, reflecting a 90% margin for the quarter, driven by internalization synergies and disciplined expense management.

• Significant balance sheet strengthening through $250 million senior notes issuance, restructuring of preferred securities, and enhanced capital flexibility.

• Portfolio resilience highlighted by strong performance from EMPAVELI, ORSERDU, XENPOZYME, XOLAIR, and a robust pipeline of over $3 billion in potential opportunities.

• Paid a quarterly cash distribution of $0.11 per unit and reactivated the Normal Course Issuer Bid.

Financial highlights

• Total income for Q1 2026 was $50.6 million, a 15% increase year-over-year, with adjusted EBITDA of $52.8 million and a 90% margin.

• Total cash receipts were $58.4 million, with adjusted cash earnings per unit of $0.68 and declared distributions of $0.11 per unit.

• Last twelve months adjusted EBITDA was $205.1 million, with an 86% margin and LTM adjusted cash earnings per unit of $2.51.

• Cash and cash equivalents stood at $52.5 million as of March 31, 2026; credit facility availability was $502.7 million.

• Comprehensive earnings were $0.5 million, compared to a loss of $1.8 million in the prior year.

Outlook and guidance

• Expectation of slightly lower operating margins in future quarters as synergy savings are reinvested for growth.

• Focus remains on efficient execution, disciplined expense management, and long-term sustainable growth.

• Emphasis on strengthening asset risk framework and disciplined capital allocation.

• Management continues to review royalty stream acquisition opportunities and declared a quarterly distribution of $0.11 per unit for Q2 2026.

• ORSERDU and broader portfolio performance remain strong, but it is too early to revise annual guidance.